EP4731270A1 - Kombinationstherapie mit peptidrezeptor-radionuklid und dna-reparaturinhibitor - Google Patents

Kombinationstherapie mit peptidrezeptor-radionuklid und dna-reparaturinhibitor

Info

Publication number
EP4731270A1
EP4731270A1 EP24739961.1A EP24739961A EP4731270A1 EP 4731270 A1 EP4731270 A1 EP 4731270A1 EP 24739961 A EP24739961 A EP 24739961A EP 4731270 A1 EP4731270 A1 EP 4731270A1
Authority
EP
European Patent Office
Prior art keywords
integrin
peptide
amino acid
peg
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24739961.1A
Other languages
English (en)
French (fr)
Inventor
Julie L. SUTCLIFFE
Tanushree GANGULY
Rebecca Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley, University of California San Diego UCSD filed Critical University of California
Publication of EP4731270A1 publication Critical patent/EP4731270A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP24739961.1A 2023-06-20 2024-06-19 Kombinationstherapie mit peptidrezeptor-radionuklid und dna-reparaturinhibitor Pending EP4731270A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363509253P 2023-06-20 2023-06-20
PCT/US2024/034612 WO2024263637A1 (en) 2023-06-20 2024-06-19 Combination therapy with peptide receptor radionuclide and dna repair inhibitor

Publications (1)

Publication Number Publication Date
EP4731270A1 true EP4731270A1 (de) 2026-04-29

Family

ID=91853505

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24739961.1A Pending EP4731270A1 (de) 2023-06-20 2024-06-19 Kombinationstherapie mit peptidrezeptor-radionuklid und dna-reparaturinhibitor

Country Status (2)

Country Link
EP (1) EP4731270A1 (de)
WO (1) WO2024263637A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3131566B1 (de) 2014-04-15 2022-10-05 The Regents of the University of California Bi-terminale pegylierte integrinbindende peptide und verfahren zur verwendung davon
JP7081832B2 (ja) 2016-06-13 2022-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア α（Ｖ）β（６）インテグリン結合ペプチドおよびその使用方法
EP3846858A4 (de) 2018-09-07 2022-10-19 The Regents of the University of California Alpha-(v)beta(6)integrin-bindende peptide und verfahren zur verwendung davon
EP3906061A4 (de) * 2019-01-04 2023-04-05 Actinium Pharmaceuticals, Inc. Verfahren zur krebsbehandlung mit kombinationen von parp-inhibitoren und antikörper-radiokonjugaten

Also Published As

Publication number Publication date
WO2024263637A1 (en) 2024-12-26

Similar Documents

Publication Publication Date Title
US11485758B2 (en) Bi-terminal pegylated integrin-binding peptides and methods of use thereof
US10464985B2 (en) Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
US12023391B2 (en) Alpha(v)beta(6) integrin-binding peptides and methods of use thereof
US20100021379A1 (en) Chemical Antibodies for Immunotherapy and Imaging
US20230183317A1 (en) Methods of detecting and treating lung damage in respiratory-related viral infections
AU2019335513A1 (en) Alpha(v)beta(6) integrin-binding peptides and methods of use thereof
WO2024263637A1 (en) Combination therapy with peptide receptor radionuclide and dna repair inhibitor
EP4317188A1 (de) Radioaktiver komplex eines anti-egfr-antikörpers und radiopharmazeutikum
EA050335B1 (ru) Радиоактивный комплекс анти-egfr антитела и радиофармацевтическое средство
HK1234666B (en) Bi-terminal pegylated integrin-binding peptides and methods of use thereof
HK1234666A1 (en) Bi-terminal pegylated integrin-binding peptides and methods of use thereof
Flook Novel α-MSH peptide analogs for melanoma targeting

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR